Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
282 studies found for:    diabetes and type 1 and open and active | Open Studies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Insulin glargine (U300) HOE901;   Drug: Insulin glargine HOE901;   Drug: Insulin glulisine HMR1964;   Drug: Insulin aspart;   Drug: Insulin lispro
2 Recruiting Evaluation of Automated Insulin Pump Settings Using the MD-Logic Advise4U
Condition: Type 1 Diabetes
Interventions: Device: MD-Logic Pump Advisor;   Other: Control Group
3 Recruiting Cross-over Study to Evaluate the Safety and Efficacy of Night Closed-loop Control Using the MD-Logic Automated Insulin Delivery System Compared to Sensor Augmented Pump Therapy in Poorly Controlled Patients With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Device: MD- Logic Closed Loop System;   Device: sensor augmented pump therapy
4 Not yet recruiting Closed Loop From Onset in Type 1 Diabetes
Conditions: Diabetes Mellitus;   Type 1 Diabetes
Interventions: Device: FlorenceM;   Other: Multiple Daily Injections
5 Not yet recruiting Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Other: 5-day intervention with single-hormone closed-loop strategy;   Other: 5-day intervention with sensor-augmented pump therapy;   Other: 5-day intervention with dual-hormone closed-loop strategy;   Device: Insulin pump;   Device: Continuous glucose monitoring system;   Drug: Insulin;   Drug: Glucagon
6 Not yet recruiting Day and Night Closed-loop in Young People With Type 1 Diabetes
Conditions: Diabetes Mellitus;   Diabetes Mellitus, Type 1;   Glucose Metabolism Disorders;   Endocrine System Diseases;   Autoimmune Diseases
Interventions: Device: FlorenceM;   Device: Insulin pump therapy
7 Recruiting An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide;   Drug: Albiglutide
8 Not yet recruiting Closed-loop Control of Glucose Levels (Artificial Pancreas) for 2 Weeks in Adults With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Other: 2-week intervention with sensor-augmented pump therapy;   Other: 2-week intervention with single-hormone closed-loop strategy;   Other: 2-week intervention with dual-hormone closed-loop strategy;   Device: Insulin pump;   Device: Continuous glucose monitoring system;   Drug: Insulin;   Drug: Glucagon
9 Not yet recruiting Closed-loop Control of Glucose Levels (Artificial Pancreas) for 2 Weeks in Adolescents and Adults With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Other: 15-week intervention with sensor-augmented pump;   Other: 15-week intervention with single-hormone closed-loop;   Other: 15-week intervention with dual-hormone closed-loop;   Device: Insulin pump;   Device: Continuous glucose monitoring system;   Drug: Insulin;   Drug: Glucagon
10 Not yet recruiting Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients
Condition: Type I Diabetes
Interventions: Biological: Wockhardt's Insulin Analogue (Recomb);   Biological: Lantus®
11 Recruiting A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin, Onglyza;   Drug: Dapagliflozin, Farxiga;   Drug: Glargine insulin;   Drug: Metformin XR
12 Recruiting Physical Activity and Glycemic Control in Adolescents
Condition: Type 1 Diabetes
Interventions: Behavioral: Reinforcement for meeting targeted physical activity goals;   Other: Standard of Care
13 Recruiting Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: insulin glargine (U300);   Drug: insulin glargine;   Drug: fast-acting insulin analogue
14 Recruiting Cross-sectional, Case Control Study of Neurocognitive Performance During Hyperglycemia , and Brain Tissue Integrity in Youth With Type 1 Diabetes and in Healthy
Condition: Diabetes Mellitus, Type 1
Interventions: Device: MRI including DTI , EEG, CGMS;   Behavioral: Neurocognitive tests
15 Not yet recruiting Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Device: MiniMed™640G and Suspend before low;   Device: MiniMed™640G
16 Recruiting Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
17 Not yet recruiting Safety and Efficacy of Artificial Pancreas With and Without a Meal Detection Module on Glycemic Control in Adolescents With Type 1 Diabetes After a Missed Bolus
Condition: Diabetes Mellitus, Type 1
Interventions: Other: Missed Bolus Intervention;   Device: Insulin infusion pump;   Other: Meals;   Drug: Human insulin
18 Recruiting Closed-loop Control of Postprandial Glucose Levels After Meals With Different Macronutrients Content in Adults With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Device: Patient's insulin pump;   Drug: Insulin;   Device: Dexcom G4 Platinum glucose sensor;   Other: Single-hormone closed-loop
19 Recruiting Bright 1 Bodies Weight Management Program
Condition: Diabetes Mellitus, Type 1
Intervention: Behavioral: Bright 1 Bodies
20 Not yet recruiting Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Other: 6-day intervention with sensor-augmented pump therapy;   Other: 6-day intervention with single-hormone closed-loop strategy;   Other: 6-day intervention with dual-hormone closed-loop strategy;   Drug: Insulin;   Drug: Glucagon;   Device: Continuous Glucose Monitoring System Enlite sensor®, Medtronic;   Device: Insulin pump MiniMed® Paradigm® Veo™, Medtronic

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.